Effects of Combination Therapy With an α1-blocker (Sustained-release Preparation of Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in the Treatment of Patients With Mild to Moderate Essential Hypertension

The purpose of this study is to investigate the efficacy and safety of Bunazosin with Valsartin compared to Doxazosin with Valsartin for patients with mild to moderate essential hypertension accompanied by metabolic syndrome.

Start Date01 Oct 2005

Sponsor / Collaborator

Eisai, Inc.

[+1]

100 Clinical Results associated with Bunazosin Hydrochloride

100 Translational Medicine associated with Bunazosin Hydrochloride

100 Patents (Medical) associated with Bunazosin Hydrochloride

276

Literatures (Medical) associated with Bunazosin Hydrochloride

13 Nov 2023·Investigative Opthalmology & Visual Science

Topical Application of Bunazosin Hydrochloride Suppresses Myopia Progression With an Increase in Choroidal Blood Perfusion

Article

Author: Jeong, Heonuk ; Kurihara, Toshihide ; Jiang, Xiaoyan ; Negishi, Kazuno ; Lee, Deokho ; Tsubota, Kazuo

PurposeThe incidence of myopia has rapidly increased in recent decades, making it a growing public health concern worldwide. Interventions to suppress the progression of myopia are needed; one suggested strategy is the prevention of choroidal thinning, which can improve choroidal blood perfusion (ChBP). Bunazosin hydrochloride (BH) is an alpha1-adrenergic blocker and commercialized glaucoma eye drop that increases in blood circulation in the eye. In this study, we evaluated the efficacy of BH in suppressing the progression of myopia in a lens-induced murine model.MethodsLens-induced myopia was induced in 3-week-old C57BL/6 J mice with -30 diopter (D) lenses for three weeks. Refractive error, axial length, and choroidal thickness were evaluated at three and six weeks of age using an infrared photorefractor and a spectral domain optical coherence tomography (OCT) system. Moreover, ChBP and scleral thickness were evaluated using swept-source OCT and histological analysis.ResultsCompared with the controls, the administration of BH eye drops suppressed the myopic shift of refractive error (mean difference ± standard error in the eye with -30 D lens, -13.65 ± 5.69 D vs. 2.55 ± 4.30 D; P < 0.001), axial elongation (0.226 ± 0.013 mm vs. 0.183 ± 0.023 mm; P < 0.05), choroidal thinning (-2.01 ± 1.80 µm vs. 1.88 ± 1.27 µm; P < 0.001), and scleral thinning (11.41 ± 3.91 µm vs. 19.72 ± 4.01 µm; P < 0.01) with myopia progression and increased ChBP (52.0% ± 4.1% vs. 59.5% ± 6.3%; P < 0.05). The suppressive effect of BH eye drops was dose-dependent and higher than that of other glaucoma eye drops and alpha1 blockers.ConclusionsThese results demonstrate the potential of BH eye drops in the treatment of myopia and support further investigation of their efficacy in humans. Further studies are needed to determine the mechanism of action and long-term safety of this treatment.

01 Feb 2017·Biosensors and BioelectronicsQ1 · ENGINEERING & TECHNOLOGY

Nanodiamonds on tetrahedral amorphous carbon significantly enhance dopamine detection and cell viability

Q1 · ENGINEERING & TECHNOLOGY

Article

Author: Niklas Wester ; Emilia Peltola ; Tomi Laurila ; Katherine B. Holt ; Jari Koskinen ; Vesa Myllymäki ; Leena-Sisko Johansson

We hypothesize that by using integrated carbon nanostructures on tetrahedral amorphous carbon (ta-C), it is possible to take the performance and characteristics of these bioelectrodes to a completely new level. The integrated carbon electrodes were realized by combining nanodiamonds (NDs) with ta-C thin films coated on Ti-coated Si-substrates. NDs were functionalized with mixture of carboxyl and amine groups ND_andante or amine ND_amine, carboxyl ND_vox or hydroxyl groups ND_H and drop-casted or spray-coated onto substrate. By utilizing these novel structures we show that (i) the detection limit for dopamine can be improved by two orders of magnitude [from 10µM to 50nM] in comparison to ta-C thin film electrodes and (ii) the coating method significantly affects electrochemical properties of NDs and (iii) the ND coatings selectively promote cell viability. ND_andante and ND_H showed most promising electrochemical properties. The viability of human mesenchymal stem cells and osteoblastic SaOS-2 cells was increased on all ND surfaces, whereas the viability of mouse neural stem cells and rat neuroblastic cells was improved on ND_andante and ND_H and reduced on ND_amine and ND_vox. The viability of C6 cells remained unchanged, indicating that these surfaces will not cause excess gliosis. In summary, we demonstrated here that by using functionalized NDs on ta-C thin films we can significantly improve sensitivity towards dopamine as well as selectively promote cell viability. Thus, these novel carbon nanostructures provide an interesting concept for development of various in vivo targeted sensor solutions.

01 Jun 2014·EndocrinologyQ2 · MEDICINE

Repetitive Hypoglycemia Increases Circulating Adrenaline Level with Resultant Worsening of Intimal Thickening After Vascular Injury in Male Goto-Kakizaki Rat Carotid Artery

Q2 · MEDICINE

Article

Author: Ohmura, Chie ; Kawamori, Ryuzo ; Mita, Tomoya ; Azuma, Kosuke ; Watada, Hirotaka ; Kanazawa, Akio ; Fujitani, Yoshio ; Osonoi, Yusuke ; Yasunari, Eisuke ; Goto, Hiromasa

Hypoglycemia associated with diabetes management is a potential risk for cardiovascular diseases. However, the effect of hypoglycemic episodes including a surge of sympathetic activity on the progression of neointima formation after vascular injury remains largely unknown. In this study, insulin was injected intraperitoneally into nonobese diabetic Goto-Kakizaki (GK) rats, once every 3 days for 4 weeks after balloon injury of carotid artery to induce hypoglycemia. Then, we evaluated balloon injury-induced neointima formation. Insulin treatment enhanced neointima formation and increased the number of proliferating cell nuclear antigen (PCNA)-positive cells in the carotid artery. Injection of glucose with insulin prevented hypoglycemia and abrogated intimal thickening. Also, bunazosin, an α1 adrenergic receptor antagonist, prevented intimal thickening and accumulation of PCNA-positive cells induced by insulin treatment despite the presence of concomitant hypoglycemia and high adrenaline levels. Incubation of cultured smooth muscle cells with adrenaline resulted in a significant increase in their proliferation and G0/G1 to S phase progression, which was associated with activation of extracellular signal-regulated kinase, enhanced expression of cell cycle regulatory molecules such as cyclin D1, and cyclin E, and phosphorylation of retinoblastoma protein. These adrenaline-induced effects were abrogated by bunazosin. Our data indicated that increased adrenaline induced by repetitive hypoglycemia promotes intimal thickening and smooth muscle cell proliferation after endothelial denudation in GK rats.

100 Deals associated with Bunazosin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01887	Bunazosin Hydrochloride	C02	DB12230

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	JP	Santen Pharmaceutical Co., Ltd.	20 Jun 2001
Heart Failure	JP	Eisai Co., Ltd.	28 Feb 1995
Essential Hypertension	JP	Eisai Co., Ltd.	16 Apr 1985
Hypertension, Renal	JP	Eisai Co., Ltd.	16 Apr 1985

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2003	Not Applicable	-	-	Bunazosin Hydrochloride 0.01%	wustdfyjtk(rnhhzokwnd) = ekvedsbjps zirtamjpae (xaczlcfqfb )	Positive	01 May 2003
ARVO2002	Not Applicable	-	-	Nipradilol (1%)	(asrdvdxeij) = zetvnbfjdf zxmbciktpr (jyrxctfhvw )	Positive	01 Dec 2002
ARVO2002	Not Applicable	-	-	Timolol (0.5%) and Bunazosin (0.125%)	(asrdvdxeij) = bxzwtquqpl zxmbciktpr (jyrxctfhvw )	Positive	01 Dec 2002

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Bunazosin Hydrochloride

Overview

Basic Info

Structure

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation